首頁 › 心血管疾病 › 阿拉巴馬州 › Huntsville
Huntsville, AL 的 心血管疾病 臨床試驗
8 項針對 心血管疾病 的研究正在 Huntsville（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
招募中4 期
- Heart Center Research, LLC, Huntsville
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
招募中2 期
- Heart Center Research, LLC, Huntsville
Product Surveillance Registry
招募中觀察性研究
- Huntsville, Huntsville
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
招募中3 期
- Clinical Trial Site, Huntsville
- Clinical Trial Site, Huntsville
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
招募中3 期
- Heart Center Research Llc, Huntsville
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
招募中3 期
- Research Site, Huntsville
- Research Site, Athens · 距離 22 英里
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
招募中3 期
- Heart Center Research LLC, Huntsville
Pivotal Study for the Cardiac Performance System (CPS)
招募中觀察性研究
- Huntsville Hospital Heart Center, Huntsville
其他城市的 心血管疾病 試驗
- Boston, MA37 項研究
- New York City, NY33 項研究
- Washington, DC28 項研究
- Houston, TX24 項研究
- Dallas, TX23 項研究
- Atlanta, GA22 項研究
- Cleveland, OH22 項研究
- Chicago, IL21 項研究
- Philadelphia, PA21 項研究
- Pittsburgh, PA20 項研究
- St. Louis, MO20 項研究
- Nashville, TN18 項研究
Huntsville 的其他研究
- 肥胖症7 項研究
- 冠狀動脈疾病6 項研究
- 心臟衰竭6 項研究
- 重度憂鬱症6 項研究
- 第二型糖尿病6 項研究
- 憂鬱症6 項研究
- 動脈硬化5 項研究
- 過重5 項研究
- 主動脈瓣狹窄4 項研究
- 慢性腎臟病4 項研究
- 心臟病發3 項研究
- 癌症（所有類型）3 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。